Schedule 13G/A
TRDA Schedule 13G/A filing by T. Rowe Price Associates
T. Rowe Price Associates reported beneficial ownership of 3.0M shares, representing 8.2% of Entrada Therapeutics, Inc. in this filing.
FiledNov 14, 2024
Ownership dateSep 30, 2024
Reported shares3.0M
Reported ownership8.2%
Ownership details
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
Sole voting power
3.0M
Shared voting power
3.0M
Sole dispositive power
3.0M
Shared dispositive power
3.0M
Price context
Price dates alongside the ownership filing
Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.
Close near filing date$19.04as of Nov 14, 2024
Latest tracked price$7.06as of Aug 5, 2026
Source
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- T. Rowe Price Associates
- CIK
- CIK0000080255
- Accession
- 0000080255-24-001476
- Form
- Schedule 13G/A
Read the filing in context